

## Metivier, Jacob

---

**From:** PIDDINGTON Amie <amie.piddington@chiesi.com>  
**Sent:** Tuesday, May 23, 2023 3:52 PM  
**To:** AGO - High Cost Prescription Drugs  
**Cc:** WHITE Donna  
**Subject:** New Drug Notice - Elfabrio

**Follow Up Flag:** Follow up  
**Flag Status:** Flagged

**EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.**

Dear Sir or Madam,

Chiesi USA would like to announce the approval of a new drug. Elfabrio was commercially listed 5/23/2023. Please see information below:

Manufacturer Name	NDC	Name of Prescription Drug
Chiesi USA	10122016002	Elfabrio One single dose vial in a carton
Chiesi USA	10122016005	Elfabrio Five Single dose vials in a carton
Chiesi USA	10122016010	Elfabrio Ten single dose vials in a carton

Sincerely,

Amie Piddington

**Amie Piddington, CCEP**  
*Compliance Specialist II*

**Chiesi USA, Inc.**  
175 Regency Woods Place, Ste. 600, Cary, NC 27518 (USA)  
Office +1 (888) 466-6505 x1673  
Mobile +1 (202) 760-1386

[www.chiesiusa.com](http://www.chiesiusa.com)



**Certified**



This company meets high standards of social and environmental impact

**Corporation**

The information transmitted is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. If the reader of this message is not the intended recipient, you are hereby notified that your access is unauthorized, and any review, dissemination, distribution or copying of this message including any attachments is strictly prohibited. If you are not the intended recipient, please contact the sender and delete the material from any computer. Personal identifying information exchanged with Chiesi via email is subject to our [Privacy Policy](#).